Pear Bio

Pear Bio is dedicated to advancing patient-centered cancer precision medicine through innovative biotechnology research. Utilizing a proprietary computational biology platform, Pear Bio meticulously analyzes patient tumor samples and data to unravel the complexities of cancer biology. This approach drives both functional precision medicine and the discovery of novel drugs.

Pear Bio’s platform employs microphysiological systems and 3D computer vision to meticulously measure cancer progression over time. By culturing patient tumor samples with matched blood into 3D immune-microtumors, Pear Bio rigorously tests potential treatment options and combinations ex vivo. This process is enhanced by a proprietary computer vision/DL pipeline that identifies image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is then carefully compared using these image biomarkers to predict the most effective treatments for each patient.

Pear Bio's commitment extends to a multi-omics pipeline, which utilizes patient data and excess tissue/blood to identify novel druggable targets in patients who do not respond to approved therapies. These targets are then integrated into Pear Bio's in-house drug discovery pipeline, ultimately feeding back into clinical care through their predictive biomarker platform. The primary address for Pear Bio is in London, GB, with an additional location in Boston, Massachusetts, US. We invite the management team at Pear Bio to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.